Corticotropin releasing factor receptor antagonists

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 12115166
APP PUB NO 20230414627A1
SERIAL NO

18307718

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention provides novel pharmaceutical compositions comprising -(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
SPRUCE BIOSCIENCES INC548 MARKET STREET SUITE 74589 SAN FRANCISCO CA 94105

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Gerber, Hal South San Francisco, US 14 82
Howerton, Alexis South San Francisco, US 14 82
Huang, Michael South San Francisco, US 62 1596

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Apr 15, 2028
7.5 Year Payment $3600.00 $1800.00 $900.00 Apr 15, 2032
11.5 Year Payment $7400.00 $3700.00 $1850.00 Apr 15, 2036
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00